257 related articles for article (PubMed ID: 37316802)
21. Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O
Cloughesy T; Finocchiaro G; Belda-Iniesta C; Recht L; Brandes AA; Pineda E; Mikkelsen T; Chinot OL; Balana C; Macdonald DR; Westphal M; Hopkins K; Weller M; Bais C; Sandmann T; Bruey JM; Koeppen H; Liu B; Verret W; Phan SC; Shames DS
J Clin Oncol; 2017 Jan; 35(3):343-351. PubMed ID: 27918718
[TBL] [Abstract][Full Text] [Related]
22. Bevacizumab and re-irradiation for recurrent high grade gliomas: does sequence matter?
Palmer JD; Bhamidipati D; Song A; Eldredge-Hindy HB; Siglin J; Dan TD; Champ CE; Zhang I; Bar-Ad V; Kim L; Glass J; Evans JJ; Andrews DW; Werner-Wasik M; Shi W
J Neurooncol; 2018 Dec; 140(3):623-628. PubMed ID: 30182159
[TBL] [Abstract][Full Text] [Related]
23. Comparative efficacy and safety of therapeutics for elderly glioblastoma patients: A Bayesian network analysis.
Zhao B; Wu J; Xia Y; Li H; Wang Y; Qu T; Xing H; Wang Y; Ma W
Pharmacol Res; 2022 Aug; 182():106316. PubMed ID: 35724820
[TBL] [Abstract][Full Text] [Related]
24. Diffusion MRI Phenotypes Predict Overall Survival Benefit from Anti-VEGF Monotherapy in Recurrent Glioblastoma: Converging Evidence from Phase II Trials.
Ellingson BM; Gerstner ER; Smits M; Huang RY; Colen R; Abrey LE; Aftab DT; Schwab GM; Hessel C; Harris RJ; Chakhoyan A; Gahrmann R; Pope WB; Leu K; Raymond C; Woodworth DC; de Groot J; Wen PY; Batchelor TT; van den Bent MJ; Cloughesy TF
Clin Cancer Res; 2017 Oct; 23(19):5745-5756. PubMed ID: 28655794
[No Abstract] [Full Text] [Related]
25. Neoadjuvant bevacizumab and irinotecan versus bevacizumab and temozolomide followed by concomitant chemoradiotherapy in newly diagnosed glioblastoma multiforme: A randomized phase II study.
Hofland KF; Hansen S; Sorensen M; Engelholm S; Schultz HP; Muhic A; Grunnet K; Ask A; Costa JC; Kristiansen C; Thomsen C; Poulsen HS; Lassen U
Acta Oncol; 2014 Jul; 53(7):939-44. PubMed ID: 24456504
[TBL] [Abstract][Full Text] [Related]
26. The addition of chloroquine and bevacizumab to standard radiochemotherapy for recurrent glioblastoma multiforme.
Witte HM; Riecke A; Steinestel K; Schulz C; Küchler J; Gebauer N; Tronnier V; Leppert J
Br J Neurosurg; 2024 Apr; 38(2):404-410. PubMed ID: 33590799
[TBL] [Abstract][Full Text] [Related]
27. Tumor treating field therapy in combination with bevacizumab for the treatment of recurrent glioblastoma.
Omar AI
J Vis Exp; 2014 Oct; (92):e51638. PubMed ID: 25407354
[TBL] [Abstract][Full Text] [Related]
28. Optimal Therapies for Recurrent Glioblastoma: A Bayesian Network Meta-Analysis.
Chen W; Wang Y; Zhao B; Liu P; Liu L; Wang Y; Ma W
Front Oncol; 2021; 11():641878. PubMed ID: 33854975
[TBL] [Abstract][Full Text] [Related]
29. The efficacy and toxicity of maintenance therapy with bevacizumab plus pemetrexed versus bevacizumab/pemetrexed alone for stage IIIB/IV nonsquamous non-small cell lung cancer: A meta-analysis of randomized controlled trials.
Liu M; Luo N; Fang Z; Liu Q; Yi F; Wei Y; Zhang X; Zhang W
J Clin Pharm Ther; 2022 Feb; 47(2):157-167. PubMed ID: 34617297
[TBL] [Abstract][Full Text] [Related]
30. Survival outcome of early versus delayed bevacizumab treatment in patients with recurrent glioblastoma.
Hamza MA; Mandel JJ; Conrad CA; Gilbert MR; Yung WK; Puduvalli VK; DeGroot JF
J Neurooncol; 2014 Aug; 119(1):135-40. PubMed ID: 24803001
[TBL] [Abstract][Full Text] [Related]
31. Prognostic factors in recurrent glioblastoma patients treated with bevacizumab.
Schaub C; Tichy J; Schäfer N; Franz K; Mack F; Mittelbronn M; Kebir S; Thiepold AL; Waha A; Filmann N; Banat M; Fimmers R; Steinbach JP; Herrlinger U; Rieger J; Glas M; Bähr O
J Neurooncol; 2016 Aug; 129(1):93-100. PubMed ID: 27193554
[TBL] [Abstract][Full Text] [Related]
32. Increased infiltration of CD8 T cells in recurrent glioblastoma patients is a useful biomarker for assessing the response to combined bevacizumab and lomustine therapy.
Lin P; Jiang H; Zhao YJ; Pang JS; Liao W; He Y; Lin ZY; Yang H
Int Immunopharmacol; 2021 Aug; 97():107826. PubMed ID: 34091114
[TBL] [Abstract][Full Text] [Related]
33. The earlier the better? Bevacizumab in the treatment of recurrent MGMT-non-methylated glioblastoma.
Schaub C; Schäfer N; Mack F; Stuplich M; Kebir S; Niessen M; Tzaridis T; Banat M; Vatter H; Waha A; Herrlinger U; Glas M
J Cancer Res Clin Oncol; 2016 Aug; 142(8):1825-9. PubMed ID: 27318492
[TBL] [Abstract][Full Text] [Related]
34. First-line bevacizumab contributes to survival improvement in glioblastoma patients complementary to temozolomide.
Hata N; Mizoguchi M; Kuga D; Hatae R; Akagi Y; Sangatsuda Y; Amemiya T; Michiwaki Y; Fujioka Y; Takigawa K; Suzuki SO; Yoshitake T; Togao O; Hiwatashi A; Yoshimoto K; Iihara K
J Neurooncol; 2020 Feb; 146(3):451-458. PubMed ID: 32020475
[TBL] [Abstract][Full Text] [Related]
35. Bevacizumab for Patients with Recurrent Multifocal Glioblastomas.
Burger MC; Breuer S; Cieplik HC; Harter PN; Franz K; Bähr O; Steinbach JP
Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29156610
[TBL] [Abstract][Full Text] [Related]
36. Bevacizumab and gamma knife radiosurgery for first-recurrence glioblastoma.
Zhang JF; Okai B; Iovoli A; Goulenko V; Attwood K; Lim J; Hess RM; Abad AP; Prasad D; Fenstermaker RA
J Neurooncol; 2024 Jan; 166(1):89-98. PubMed ID: 38175460
[TBL] [Abstract][Full Text] [Related]
37. Implications of bevacizumab discontinuation in adults with recurrent glioblastoma.
Anderson MD; Hamza MA; Hess KR; Puduvalli VK
Neuro Oncol; 2014 Jun; 16(6):823-8. PubMed ID: 24596117
[TBL] [Abstract][Full Text] [Related]
38. Patterns of progression in patients with recurrent glioblastoma treated with bevacizumab.
Pope WB; Xia Q; Paton VE; Das A; Hambleton J; Kim HJ; Huo J; Brown MS; Goldin J; Cloughesy T
Neurology; 2011 Feb; 76(5):432-7. PubMed ID: 21282590
[TBL] [Abstract][Full Text] [Related]
39. Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial.
Herrlinger U; Schäfer N; Steinbach JP; Weyerbrock A; Hau P; Goldbrunner R; Friedrich F; Rohde V; Ringel F; Schlegel U; Sabel M; Ronellenfitsch MW; Uhl M; Maciaczyk J; Grau S; Schnell O; Hänel M; Krex D; Vajkoczy P; Gerlach R; Kortmann RD; Mehdorn M; Tüttenberg J; Mayer-Steinacker R; Fietkau R; Brehmer S; Mack F; Stuplich M; Kebir S; Kohnen R; Dunkl E; Leutgeb B; Proescholdt M; Pietsch T; Urbach H; Belka C; Stummer W; Glas M
J Clin Oncol; 2016 May; 34(14):1611-9. PubMed ID: 26976423
[TBL] [Abstract][Full Text] [Related]
40. Patterns of bevacizumab use in patients with glioblastoma: an online survey among experts in neuro-oncology.
Ranjan S; Skorupan N; Ye X; Sivakumar A; Yankulina O; Kamson D; Grossman SA; Dzaye O; Holdhoff M
Neurooncol Pract; 2020 Jan; 7(1):52-58. PubMed ID: 32257284
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]